Introduction
Blood plasma contains a combination of sub-proteomes derived from different tissues, and thus, it potentially provides a window into an individual's state of health. Therefore, a detailed analysis of the plasma proteome holds promise as a source of biomarkers that can be used for the diagnosis and staging of diseases, as well as for monitoring progression and response to therapy. Subsequently, the widespread adoption of LC-MS/MS techniques resulted in a rapid increase in plasma proteome-related datasets that needed to be similarly integrated to form a next-generation comprehensive human plasma proteome reference set. In 2002, the Human Proteome Organization (HUPO) launched Phase I of its Human Plasma Proteome Project (PPP) and provided reference specimens of serum and EDTA-, citrate-, and heparin-anticoagulated plasma to 55 laboratories. Eighteen laboratories contributed tandem MS findings and protein identifications, which were integrated by a collaborative process into a core dataset of 3020 proteins from the International Protein Index (IPI) database (3) containing two or more identified peptides, plus filters for smaller, higher confidence lists (4, 5) . A stringent re-analysis of the PPP data, including adjustment for multiple comparisons, yielded 889 proteins (6) . (8) (9) (10) . Only 46 were reported in all four sources, suggesting variability in the proteins detected by different methods, high false positive rates due to insufficiently stringent identification criteria, and non-uniform methods for assigning protein identifications. Shen et al. (11) reported 800 to 1682 proteins from human plasma, depending on the proteolytic enzymes used and the criteria applied for identification;
Omenn et al. (4) re-analyzed those raw spectra with HUPO PPP-I search parameters and matched only 213 to the PPP-I core dataset. Chan et al. reported 1444 unique proteins in serum using a multi-dimensional peptide separation strategy (12) , of which 1019 mapped to IPI and 257 to the PPP-I core dataset. These previous efforts highlight the challenges associated with accurately determining the number of proteins inferred from large proteomic datasets, and with comparing the proteins identified in different datasets.
In 2005, we used a uniform method based on the Trans-Proteomic Pipeline (13) to create the first Human Plasma PeptideAtlas (14) , containing 28 LC-MS/MS datasets and over 1.9 million spectra. Using a PeptideProphet (15) probability threshold of P >= 0.90, 6929
peptides were identified at a peptide false discovery rate (FDR) of 12%, as estimated by PeptideProphet's data model, mapping to about 960 distinct proteins. Comparison of protein identifiers with those from studies cited above showed quite limited overlap. The goal of the present work was to compile a larger human plasma proteome reference set of similar high confidence by creating a new release of the Human Plasma PeptideAtlas incorporating more data than in 2007 and interpreting the data using more stringent criteria. We searched raw datasets submitted to PeptideAtlas and performed peptide validation using a uniform pipeline (Figure 1 ), compiled several sets of corresponding protein identifications at different clearly-defined levels of redundancy (Figure 2) , and, using a spectral counting technique, provided a rough estimate of concentrations for a highly non-redundant set of protein sequences in order to guide blood-based diagnostic efforts such as doping using stable isotope-labeled synthetic reference peptides for SRM experiments (Figure 3) . The result is a plasma proteome reference set (Figure 4 ; Supplementary Data Tables S3 and S6) containing 1929 highly non-redundant protein sequences at an estimated 1% FDR.
Experimental Procedures

Searching of datasets
We collected raw spectra from 91 high-quality LC-MS/MS datasets ( (4, 12, (17) (18) (19) (20) (21) 
Analysis and validation of search results
The search results for each experiment were processed using the Trans-Proteomic Pipeline (TPP) (13) , as shown in Figure 1 , left (see Supplemental Data for TPP parameters used). PeptideProphet (15) computed a probability for each peptide-spectrum match (PSM) for peptides of length 7 or greater. iProphet (27) For very large datasets, the FDR at the peptide level tends to be much larger than that at the PSM level, and, at the protein level, much larger still (32) . Thus, in order to obtain a 1% decoy-estimated protein FDR for the final Human plasma PeptideAtlas, a stringent PeptideProphet-estimated PSM FDR filter of 0.0002 (corresponding to probability cutoffs ranging from 0.9903 to 0.9998) was applied to each experiment. ProteinProphet (33) was then run on each experiment, assigning to each distinct peptide the probability of its highest probability PSM, and further adjusting these probabilities using a number of sibling peptides model, which rewards peptides that map to proteins with many identified peptides.
The set of identified peptides for the HsSerum NCI Large Survey experiment (12) was found to contain many peptides that map to yeast but not human. Suspecting yeast contamination, we purged the peptide set for this experiment of all peptides that appear in the yeast genome. there is no way to determine this from the data.
To partially address this issue, we compiled several sets of protein identifications for this build at different levels of redundancy. For the purpose of this work, the redundancy of a set of protein identifications is the extent to which the set contains more sequences than necessary to reasonably explain all of the data. Note that redundancy is different from confidence and that the different redundancy levels do not correspond to different confidence levels. The four most useful protein sets are described below; the first two, exhaustive (most redundant) and canonical (least redundant), are used extensively throughout this report. All sets are summarized in Figure 2 , and a detailed explanation, including examples, is given in Supplemental Data (Cedar). We have named this scheme
Cedar to capture the somewhat tree-like pyramidal shape shown in Figure 2a . is important to understand that the label canonical is with respect to a particular data collection; a protein sequence that is identified in two atlas builds may be labeled canonical in one collection and something else in another.
The possibly-distinguished set includes protein sequences that have one or more peptides distinguishing it from all protein sequences in the canonical set, but with these peptides comprising fewer than 20% of the total number of identified peptides in each protein, making the case for independent existence less strong.
Finally, the covering set is a near-minimal set sufficient to explain all of the peptide identifications (see Supplemental Data, Cedar, for algorithm). This set consists of almost all of the canonical protein sequences plus some of the possibly-distinguished protein sequences, and is usually somewhat larger than the canonical set. It is useful for assigning a "parent" protein identification to each identified peptide, as is necessary for estimating FDR using Mayu (32) or computing the empirical observability score described in subsection 10 below.
See Supplemental Data (Cedar) for settings to apply when using the PeptideAtlas web interface to obtain these protein sequence sets.
Analysis of N-linked glycopeptide-enriched samples
We then analyzed the 22 datasets from samples prepared using N-linked glycocapture enrichment. Our aim in including these samples was to detect low-abundance proteins, many of which are N-glycosylated. Sample preparation was as described in (35) . Briefly, N-linked glycoproteins were conjugated to a solid support using hydrazide chemistry, We then constructed a Human Plasma N-Glyco PeptideAtlas using the same methods as above, but with a PSM FDR threshold of 0.00002, yielding a protein-level FDR of 0.56%. We chose this threshold to achieve our goal of a 1% protein FDR after combining with the 0.86% FDR Non-glyco build described above. It was not practical to use identical FDRs for the component builds because even fine adjustments in the PSM FDR for a component build sometimes resulted in coarse changes in the protein FDR for the combined build.
Concentration estimation
Spectral counting was applied to roughly estimate the absolute concentration of the group representative for each ProteinProphet protein group in each atlas. Spectral counting rests on the observation that the PSM count for a peptide correlates linearly with its molar concentration in the sample (38) . We applied a simplification of the APEX method described by Lu and co-workers (39 
We calibrated the concentration scale to the published concentrations of individual proteins. In Figure 3 , we plot NSC i versus concentrations determined via immunoassay and antibody microarray in (40) . In many cases, these concentrations reflect multiple isoforms and/or cross-reacting proteins. Using the slope S and y-intercept K from this calibration plot, we then calculated an estimated concentration C i for each group representative protein sequence with NSC i >= 4
(smaller counts have been found unreliable for this purpose (41)) in the Human Plasma Non-glyco PeptideAtlas:
Concentrations were converted to mass units (ng/mL) for storage in PeptideAtlas using molecular weights calculated from amino acid sequence.
The distance of the standard deviation curve from the trend line at the center of each decade on the x-axis (between 10 0 and 10 1 , between 10 1 and 10 2 , etc.) was recorded as an uncertainty factor for the normalized PSM counts in that decade, ranging from less than 5x at high concentrations to 13x at low concentrations. See Supplemental Data, Table S2, for complete listing. The calibration plot is shown in Supplemental Data ( Figure S2 ). Also shown is a plot correlating the estimated concentrations in the Non-glyco and N-Glyco atlases for protein sequences appearing in both ( Figure S3 ).
Construction of combined PeptideAtlas plasma build
Finally, we combined the PSMs and peptides from these two atlases to form a Human Plasma PeptideAtlas build that includes results from all 91 plasma (or serum)
experiments, both non-glycocapture and glycocapture. We ran ProteinProphet on the combined set of experiments and created protein identification sets as described above.
Estimated concentrations from the Non-glyco atlas were used for protein sequences with values in both contributing atlases.
False discovery rate
Mayu, a software tool for estimating false discovery rates of protein identifications in large-scale datasets (32), was applied to each component atlas and to the combined atlas to estimate the protein-level FDR.
Mayu implements a refinement of the common decoycounting approach, improving accuracy by taking into consideration the size of the dataset, the number of tryptic peptides in each protein, and proteome coverage.
Manual validation of single-PSM protein identifications
Three hundred fifty-seven of the 1999 canonical protein identifications that emerged after combining the Non-glyco and N-Glyco builds were supported by only a single PSM (Supplemental Data, Table S5 ). We manually validated these, judging a PSM positively for each of the following: identifications to b-or y-ions or neutral losses for nearly all of the tallest peaks in the spectrum, at least one series of four or more consecutive highly abundant fragment ions of the same type (b or y, preferably y) and charge state, highly abundant fragments corresponding to cleavage N-terminal to proline and C-terminal to aspartic acid (42) , no missed tryptic cleavages, fragments observed above the noise level for at least 50% of the expected ions, internal positively-charged amino acids to account for precursor charges above +2, and N-terminal acetylation only for peptides at Nterminus of protein. We discarded 70 PSMs that failed to fulfill these criteria to the extent that, in our opinion, they had a greater than 10% chance of being incorrect identifications.
So the user can view these 70 discarded identifications, they were not removed from the component (N-Glyco and Non-glyco) atlases.
9. Construction of combined PeptideAtlas plasma build at 5% protein FDR We repeated the above atlas construction procedure to obtain a combined build with a protein FDR of approximately 5%, as follows. We applied a PSM FDR of 0.001 to the non-glyco data and a PSM FDR of 0.0007 to the glyco data, obtaining in each case a build with a Mayu protein FDR of 4.8%. These were combined to yield a "Human Plasma FDR 5% PeptideAtlas" build (actual Mayu protein FDR is 4.6%). Single-PSM identifications were not manually validated, and all that passed our computational criteria were retained in this build.
Empirical observability score
For all peptides in each atlas, we calculated an empirical observability score (EOS) (43), defined as the ratio of the number of samples in which a given peptide is observed divided by the number of samples in which the parent protein sequence is observed. For example, if peptide X is seen in 5 different samples and its parent protein sequence is observed in 10 samples, the EOS is 0.5.
Results
Size, confidence, and completeness of proteome reference set
The 2010 Human Plasma PeptideAtlas, constructed from 91 LC-MS/MS datasets, contains 1929 canonical protein sequences with an estimated protein FDR of <0.98%
( Figure 4 and Supplemental Data, Table S3 ). As described in Experimental Procedures, the set of canonical protein sequences is a highly non-redundant protein sequence set with no protein sequence sharing more than 80% of its observed peptides with any other member of the set. This criterion may exclude closely related protein family members.
The list of 1929 protein identifiers, along with estimated concentrations and number of supporting PSMs and distinct peptides, is given in Supplemental Data (Table S6) .
Each canonical protein sequence in the Human Plasma PeptideAtlas is supported by between 1 and 521 distinct observed peptides (mean=11, median=3) and between 1 and 390,366 PSMs (mean=1720, median=10). Of the 1929 canonical protein sequences, 1642
are supported by more than one PSM, and 1313 are supported by more than one distinct peptide.
High confidence identifications
The previous Human Plasma PeptideAtlas contained 27,801 peptides mapping to 2738 non-redundant proteins (protein redundancy level corresponding roughly to that of the covering list for the 2010 atlas). The 2010 Human Plasma PeptideAtlas contains fewer identified peptides and protein sequences, but these fulfill much more stringent criteria.
For lack of suitable methods, we could not accurately estimate the protein FDR of the its protein FDR is no doubt much higher than the 1% of the 2010 build. The high confidence level for the 2010 build, and the ability to estimate it, were accomplished by the inclusion of more data plus four methodological improvements:
Spectral library searching: Non-glyco query spectra were compared against consensus spectra derived from real spectra, rather than against theoretical spectra. This resulted in better discrimination between true and false identifications (24) , giving a higher number of identifications at any given PSM FDR.
iProphet: A new component of the Trans-Proteomic Pipeline, iProphet (27) , increased discrimination between true and false identifications in our atlas builds by modeling five additional properties of the data beyond those modeled by PeptideProphet (see
Experimental Procedures).
PSM FDR cutoff: For the 2007 build, we used a PSM probability cutoff of 0.9. Because experiments vary in the quality of their results, this uniform probability cutoff admitted a higher proportion of false PSMs for poor experiments than for high quality experiments.
Therefore, here we instead used a PSM FDR threshold, adjusted to achieve a protein FDR of about 1% for the combined build. Corresponding probability cutoffs were one to three orders of magnitude more stringent than those for the 2007 build, admitting many fewer PSMs per experiment.
Decoy-estimated protein FDR: By including decoys in our target database we were able to apply the recently-developed tool Mayu to accurately estimate the protein FDR. To the extent that these roughly estimated values are accurate, the very large amount of data contributes to the accuracy. Data heterogeneity may also add to accuracy by allowing averaging over many diverse samples. However, it may also detract because of the variety of instruments and settings used. Dynamic exclusion settings, for example, can be optimized to amplify the spectral counts of low abundance proteins relative to the counts for high abundance proteins (49); the mixing of results in PeptideAtlas from experiments with optimized and non-optimized settings could reduce accuracy.
Single-PSM protein identifications
Obviously, estimated concentrations are sensitive to the calibration values used; see Figure S4 , Supplemental Data, for illustration.
Concentration is estimated for the group representative for each protein group (as long as its ProteinProphet-adjusted PSM count is at least 4). This concentration must be considered to be shared among all protein sequences in the group, usually splice isoforms or paralogs. Some atlas data come from analysis of depleted samples; concentrations for depleted proteins (including those proteins that are inadvertently removed during the depletion process, see (50)) are underestimated. Plasma concentrations for cellular proteins can be elevated when there is non-physiological breakage of blood cells during sample collection and preparation. The sum of the estimated concentrations for hemoglobin-alpha and -beta, 71 g/mL, is close to the 100-200 g/mL measured in serum in (51) , suggesting that such breakage was minimal.
The estimated concentrations based on spectral counting of the canonical protein sequences in the Human Plasma PeptideAtlas span 6.5 orders of magnitude, ranging from 1.6 x 10 6 ng/mL for serum albumin (P02768) down to 0.5 ng/mL for CEACAM1 (P13688, Cardinoembryonic antigen-related cell adhesion molecule 1). Serum albumin is known to be the most abundant protein in plasma with a normal range of 3.4-5.4 x 10 7 ng/mL (2, 52), but is underestimated in the atlas due to depletion.
Fraction of identifications containing N-glycosite motif
Non-glyco PeptideAtlas
N-Glyco PeptideAtlas
Distinct peptides 3.9% 53% Canonical proteins 72% 90% Table 1 (Table 1) .
Eighty-six canonical protein sequences from the Human Plasma N-Glyco PeptideAtlas, all with estimated concentrations < 25 ng/mL, are not found in the Human Plasma Nonglyco PeptideAtlas exhaustive set (Table S7 , Supplemental Data). All but one of the 125 peptides mapping to these proteins has an N-glycosite motif. Because glycosylation hinders LC-MS/MS identification, it is highly unlikely that these peptides would be identified without the glycocapture protocol, which results in removal of glycan groups.
Indeed, only four are present in the NIST 3.0 spectral library we used to search the nonglyco data.
Of the 86 proteins, 31% have no spectra in the NIST 3.0 library and thus could not have been identified by spectral searching. However, as explained in Supplemental Data
(Completeness of spectral library searching), we expect very few additional canonical proteins would be identified were we to perform database searching on the non-glyco data. Therefore, we conclude that for nearly all of these 86 proteins, the reason they are missing from the Non-glyco atlas is because they are of low abundance in plasma. 
Missed cleavages; semi-tryptic and non-tryptic peptides
Both SpectraST and X!Tandem were set to allow matches to peptides with missed cleavages and/or peptides that were not fully tryptic; see Table 2 for tallies. Missed cleavages and non-tryptic termini are usually penalized by ProteinProphet; penalties vary depending on the software's statistical modeling of each dataset.
Contribution of trauma experiments
Our intention was to catalog the proteins found in normal plasma; therefore, the 2010
Human Plasma PeptideAtlas almost exclusively includes experiments on samples originating from individuals with no known disease state or other unusual condition. Six included experiments, however, were performed on a pool of six severe trauma patients plus one healthy subject (20) , and we found that 455, or 24%, of the canonical protein sequences in the Atlas were observed only in one or more of these experiments and not in any of the other 85, raising the question of whether these proteins are trauma-specific.
The 455 are all low abundance with at most 145 PSMs per protein; we believe that most of these are difficult-to-detect proteins present in normal plasma, rather than traumaspecific proteins, because of the advanced technology employed in the experiments (depletion of the twelve most abundant plasma proteins; fractionation into cysteinyl and non-cysteinyl peptides, glyco-and non-glycopeptide; separation of each fraction into 30 sub-fractions using strong cation exchange, analysis on a Thermo LTQ instrument), which yielded nearly twice the peptide identifications per experiment when compared to earlier experiments from the same lab (depletion of only six most abundant plasma proteins and, in some cases, a less advanced instrument (Thermo LCQ) employed) (54).
Keratins and immunoglobulins
Some keratins are common contaminants in proteomic sample processing, and the immunoglobulins are a very large class of plasma proteins consisting of similar interchangeable subunits, so one may wish to omit these classes of protein sequences from a plasma proteome reference set. We estimated the number of canonical protein sequences that belong to these classes (Table 2 ) by counting those identified as immunoglobulins or keratins in their descriptions, plus all those in the same protein group as such a sequence. We counted all keratins, even those that are internal cytokeratins and not skin contaminants. We did not count sequences annotated as immunoglobulin-like or immunoglobulin-related. Omitting these immunoglobulins and keratins leaves 1769 canonical protein sequences not belonging to these classes.
Evidence for multiple splice isoforms and single nucleotide polymorphisms (SNPs)
The human section of Swiss-Prot is curated to contain one entry per protein-coding gene, each with descriptions for known splice isoforms. There is only one Swiss-Prot entry for which two splice isoforms exist in the canonical set, and it is only this protein, mannanbinding lectin serine protease 1, which we confidently claim is present in more than one splice isoform in human plasma. Twelve additional Swiss-Prot alternative splice isoforms are noted as possibly-distinguished; we are less confident that these are present as distinct isoforms because possibly-distinguished protein sequences have only a small amount of peptide evidence distinguishing them from their canonical counterparts.
Further, 131 canonical protein sequences come from the IPI or Ensembl databases, indicating that each includes at least one observed peptide that is not mappable to any Swiss-Prot entry. These might represent SNPs or sequence errors (see IPI00887739 in
Complement C3 group in Supplementary Materials Figure S1 for an example), or protein-coding genes or splice variants not described in Swiss-Prot.
Discussion
Composition and completeness of proteome reference set
Our set of 1929 canonical protein sequences, by far the largest published so far at this confidence level, includes the highest concentration proteins as well as nearly complete coverage of the phosphoproteome described in (55) (details in Table 3 ). Still, we believe it is far from a complete catalog of the human plasma proteome. First, our reference set and the MS-derived lists in Table 3 are all biased toward proteins that are readily detectable by MS techniques; proteins missing from one list are likely to be missing in the others, so coverage of the lists in Table 3 is not indicative of complete proteome coverage.
Other proteins. Growth after PPP-1 was shallow, then jumped with the addition of experiments employing extensive depletion and fractionation and high mass accuracy instruments (19, 20) . The curve will asymptotically approach the total number of proteins detectable with the techniques used, but is not yet nearing that limit. PeptideAtlas exhaustive set, meaning that we identified no peptides for them (see Table   S8 , Supplemental Data). If the Schenk et al. data were added to the Human Plasma
PeptideAtlas, most or all of these would appear in the resulting canonical list. This supports our conclusion that more data, preferably from different laboratories using different sample sources, depletion techniques, and preparation techniques, will continue to add significant numbers of high confidence protein sequences to the human plasma proteome.
Because we searched the non-glycocapture data against a spectral library and not against a sequence database, we only identified peptides that had been previously seen in LC-MS/MS experiments and included in the NIST spectral library. However, the NIST library is extremely comprehensive, including most of the human data in the PeptideAtlas (from plasma and many other sources), so nearly all human-derived spectra identifiable with a sequence search engine with standard parameters will be identified with our spectral library search. Very few, if any, canonical proteins would be added to the Atlas were we to incorporate sequence database search results (see Supplemental Data,
Completeness of spectra library searching, for analysis).
Multi-tiered protein identifications: Alternatives for comparison of datasets
As described under Experimental Procedures, we created our exhaustive identification set by mapping all identified peptides to a combined protein sequence database containing many sequences repeated identically or with only slight variations. Removing redundancy from such a set is always a problem in interpreting proteomics data, and no standard methods have been agreed upon.
In considering this issue, it is critical to understand that virtually no protein identification list for a given dataset can be considered definitive. Once one eliminates exact duplicates, the process of removing redundancy necessarily involves choices that are somewhat arbitrary, as described in (58), and is at odds with the preservation of identifications consistent with the data. In most cases, a highly non-redundant list is necessarily a model or example list, each entry of which may represent several proteins that are as likely, or almost as likely, to exist in the sample. In particular, we emphasize that we do not claim to have definitive evidence for any of the specific isoforms in our canonical set; rather, we claim that, for each protein sequence in the set, there exists either that protein or a closely related one in at least one of the samples.
For some purposes, such as estimating the number of distinct proteins revealed by the data, a highly non-redundant protein identification set is desired. For other purposes, such as comparison with a non-redundant list for another proteome, filtering by molecular weight or pI, or selection of peptides for SRM experiment design, redundancy is desirable. As described in Experimental Procedures, we created several different protein sequence sets that could be used, alone or in combination, for different purposes.
Multi-tiered schemes are not novel and have been implemented in many proteomics studies. For example, the core dataset for PPP-I contained 3020 protein sequences, but alternative threshold criteria were used to generate several other sets including a set of 889 protein sequences using very restrictive criteria with an adjustment for multiple hypothesis testing (6) , roughly analogous to our canonical set, and an unintegrated set of 15,710 protein sequences based on only a single peptide, roughly analogous to the exhaustive set defined here.
With the current work, we make two contributions in this area. First, we present Cedar, a protein identification classification scheme based on the freely-available ProteinProphet and applicable to any search results that can be converted to mzML (59) Table S9 .
Experiment design for targeted proteomics
When a protein is observed in a sample that is analyzed with LC MS/MS techniques, some of the protein's peptides are observed many times, while others are not observed at all, despite being in the observable mass range and otherwise having attributes consistent with MS analysis (61, 62) . Several algorithms that attempt to predict observability based on sequence attributes have been put forward (39, 61, 63) ; these are heavily influenced by the data with which they are trained. As noted in Experimental Procedures, for all peptides in the Human Plasma PeptideAtlas, we calculated an empirical observability score (EOS) that does not rely on prediction algorithms; however, it is highly dependent on MS data collection parameters, including dynamic exclusion settings, as in (49) .
Since shotgun-style experiments of complex samples will always miss many proteins, especially low concentration proteins, a targeted approach in which the mass spectrometer selects only peptides contained within specific proteins of interest should be more successful, reproducible, and time efficient. Using the PeptideAtlas web interface, one can select peptides based on the EOS and other attributes, such as number of observations, number of protein mappings, missed cleavages, semi-tryptic, or multiple genome locations, and present these as an inclusion list for the mass spectrometer.
PeptideAtlas includes several other features to support SRM experiment design. For peptides belonging to proteins not yet observed in PeptideAtlas, observability scores based on sequence attributes are calculated. When multiple spectra exist for the same precursor ion, they are combined to generate a consensus spectrum that can be visualized by the user. Transition lists can be generated automatically from these consensus spectra according to user-specified rules. For absolute protein abundance measurements, the estimated protein concentrations described above allow one to spike in synthetic reference peptides at concentrations similar to those expected in the sample. These features and others are described in (43) . Finally, we and others are in the process of systematically generating reference fragment ion spectra from synthetic peptide libraries using the triple quadrupole instruments used for SRM measurements and we will make these publicly accessible as verified transition sets (64), (65) .
Conclusion
PeptideAtlas is an integral part of the ProteomeXchange infrastructure for HUPO initiatives and other worldwide data submissions (figure published in (66)), together with the ProteomeCommons.org Tranche distributed file-sharing system (67) and the EBI PRIDE (68) database. PRIDE contains the investigators' original datasets; PeptideAtlas consolidates the raw data of individual studies into re-analyzed proteome reference sets.
A significant aspect of PPP-II is the establishment of a standard method for the submission of data to the ProteomeXchange consortium. It is the policy of PPP-II that all published plasma data be submitted to Tranche or PRIDE, from which it will be stored in Tranche and incorporated into the PeptideAtlas.
The PeptideAtlas approach described here provides a framework for the continued analysis of human and other complex proteomes. Soon, MS/MS data interpretation based on translated genomes will be replaced by rich spectral libraries derived from both natural and synthetic peptide information, which outperform current database searching strategies. Already, there is a complete spectral database for the entire yeast proteome (65) 
